



Myovant Sciences to Participate in the Evercore ISI BioPharma Catalyst / Deep Dive Conference

November 21, 2017

BASEL, Switzerland, Nov. 21, 2017 /PRNewswire/ -- Myovant Sciences (NYSE: MYOV), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for women's health and endocrine diseases, today announced that Lynn Seely, M.D., President and Chief Executive Officer of Myovant Sciences and Frank Karbe, Chief Financial Officer of Myovant Sciences, will participate in a fireside chat at the Evercore ISI BioPharma Catalyst / Deep Dive Conference in Boston, Massachusetts on November 29, 2017 at 2:00 p.m. ET.



The event will be webcast live and may be accessed via the Events page under the [Investors and Media](#) section of Myovant's website at www.myovant.com. Please connect to the company's website at least 15 minutes prior to the presentation to ensure adequate time for any software download that may be required to listen to the webcast. A replay will also be available at the same location for 30 days following the conference.

About Myovant Sciences

Myovant Sciences is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for women's health and endocrine diseases. Myovant's lead product candidate is relugolix, an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone receptor antagonist. Myovant has initiated three clinical programs for relugolix consisting of five international Phase 3 clinical trials, two in women with heavy menstrual bleeding associated with uterine fibroids (LIBERTY 1 & 2), two in women with endometriosis-associated pain (SPIRIT 1 & 2), and one in men with advanced prostate cancer (HERO). Myovant is simultaneously developing MVT-602, a kisspeptin agonist, for the treatment of female infertility as part of assisted reproduction. Takeda Pharmaceuticals International AG has granted Myovant an exclusive, worldwide license to develop and commercialize relugolix (excluding Japan and certain other Asian countries where Takeda retains exclusive rights) and an exclusive license to develop and commercialize MVT-602 in all countries worldwide. Over time, the company intends to expand its development pipeline to include other potential treatments for women's health and endocrine diseases. For more information, please visit the company's website at www.myovant.com.

Investor Contact:

DeDe Sheel
Investor Relations
Myovant Sciences, Inc.
investors@myovant.com

View original content with multimedia: <http://www.prnewswire.com/news-releases/myovant-sciences-to-participate-in-the-evercore-isi-biopharma-catalyst--deep-dive-conference-300559971.html>

SOURCE Myovant Sciences